Background {#Sec1}
==========

Fluid overload (FO) is a common complication of acute illness affecting more than a third of critically ill patients and approximately two-thirds of patients with acute kidney injury (AKI) requiring renal replacement therapy (RRT) \[[@CR1], [@CR2]\]. Several studies have documented that FO is independently associated with more than 50% mortality among patients receiving RRT \[[@CR3], [@CR4]\]. Observational studies suggest that fluid removal using net ultrafiltration (UF^NET^) may be associated with improved outcomes \[[@CR2]\], and clinical and consensus guidelines recommend UF^NET^ for the treatment of FO in patients with oliguric AKI who are resistant to diuretic therapy \[[@CR5], [@CR6]\]. However, the optimal intensity of UF^NET^ (i.e., rate and volume of net fluid removal) in critically ill patients remains uncertain more than 70 years after the first clinical use of ultrafiltration \[[@CR7]\].

Less intensive UF^NET^, characterized by a slower rate or smaller volume of fluid removed, may be associated with prolonged exposure to tissue and organ edema and increased morbidity and mortality \[[@CR8], [@CR9]\]. More intensive UF^NET^ with a faster rate or larger volume of fluid removal, however, may be associated with increased hemodynamic and cardiovascular stress \[[@CR10]\], leading to ischemic organ injury and mortality in critically ill patients \[[@CR11]\]. Indeed, three observational studies in outpatients with end-stage renal disease suggest that UF^NET^ intensity \> 10 ml/kg/h is associated with increased overall \[[@CR12]--[@CR14]\] and cardiovascular \[[@CR12]\] mortality.

Understanding the relationship between UF^NET^ intensity and outcome in critically ill patients is essential for two important reasons. First, if more intensive UF^NET^ is associated with lower mortality, then clinical trials could be designed to reduce the risk of death. Second, understanding the intensity--outcome relationship will aid in standardizing UF^NET^ intensity and implementing quality measures \[[@CR15], [@CR16]\].

In this observational study involving a large heterogeneous cohort of critically ill patients with ≥ 5% FO and receiving RRT, we examined the association between UF^NET^ intensity and its association with risk-adjusted 1-year mortality. Because the magnitude of FO is independently associated with mortality, we hypothesized that intensive UF^NET^ would be associated with lower mortality. However, our null hypothesis was that there is no difference in mortality for an intensive UF^NET^ group compared with a less intensive UF^NET^ group.

Methods {#Sec2}
=======

Data source and study population {#Sec3}
--------------------------------

We conducted a retrospective study using a large tertiary care academic medical center ICU database: the High-Density Intensive Care dataset, details of which have been published elsewhere (Additional file [1](#MOESM1){ref-type="media"}: S1) \[[@CR1], [@CR17], [@CR18]\]. The study population included adults admitted to medical, cardiac, abdominal transplant, cardiothoracic, surgical, neurovascular, neurotrauma and trauma ICUs during July 2000 through October 2008. We included patients with AKI receiving RRT who had a cumulative fluid balance ≥ 5% prior to RRT initiation (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). We extracted the daily fluid balance before and for the duration of RRT (Additional file [1](#MOESM1){ref-type="media"}: S2), hourly mean arterial pressure (MAP) and vasopressor type and dose (Additional file [1](#MOESM1){ref-type="media"}: S3) during RRT. The University of Pittsburgh's institutional review board approved the study.

Determination of UF^NET^ intensity {#Sec4}
----------------------------------

For patients receiving continuous renal replacement therapy (CRRT), we first extracted data on the total duration (in hours) of any form of CRRT (i.e., continuous venovenous hemodiafiltration (CVVHDF), continuous venovenous hemofiltration (CVVH), continuous venovenous hemodialysis (CVVHD) and slow continuous ultrafiltration (SCUF)). We then determined the UF volume produced and the amount of substitution fluids given each hour for patients receiving CVVHDF and CVVH. The UF^NET^ each hour was calculated as the difference between the UF volume and the volume of substitution fluids \[[@CR19]\]. For patients receiving CVVHD and SCUF, UF^NET^ corresponded to the UF volume removed. We then calculated the total number of days of CRRT for each patient based on the hourly duration of CRRT and the total UF^NET^.

For patients receiving intermittent hemodialysis (IHD), we extracted the total number of IHD sessions and the UF volume removed per session from the time of ICU admission to the end of ICU stay. We excluded patients if they received IHD prior to ICU admission. UF^NET^ corresponded to the volume ultrafiltered during each session. We then expressed the total number of IHD sessions as the number of days for each patient. Subsequently, we estimated the UF^NET^ intensity using the equation:$$\documentclass[12pt]{minimal}
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For instance, if an 80-kg patient is on CVVH with an UF rate of 2000 ml/h and substitution fluid of 1500 ml/h, the total UF^NET^ produced is 500 ml/h (2000 -- 1500 = 500 ml) or 500 × 24 = 12,000 ml/day. The total UF^NET^ produced for 5 days is 12,000 × 5 = 60,000 ml. Thus, the total UF^NET^ intensity is \[60,000 / (80 × 5)\] = 150 ml/kg/day. During CVVHD and IHD, the UF volume is equivalent to UF^NET^.

Outcomes {#Sec5}
--------

The primary outcome was 1-year mortality from the index ICU admission and mortality data were obtained from the Social Security Death Master File \[[@CR20]\]. We chose 1-year mortality because our prior work showed that a positive fluid balance was associated with risk of death at 1 year and use of renal replacement therapy was associated with lower risk of death in patients with a positive fluid balance \[[@CR1]\]. Secondary outcomes included hospital length of stay, hospital mortality and renal recovery. Renal recovery was defined as alive *and* independent from RRT at 1 year. Dialysis dependence data were obtained from the US Renal Data System \[[@CR21]\].

Statistical analysis {#Sec6}
--------------------

We stratified UF^NET^ intensity into three groups because of the nonlinear (i.e., J-shaped) association between UF^NET^ intensity and hospital mortality (Additional file [1](#MOESM1){ref-type="media"}: Figure S2). We defined UF^NET^ ≤ 20 ml/kg/day as "low" intensity, UF^NET^ \> 20 to ≤ 25 ml/kg/day as "moderate" intensity and UF^NET^ \> 25 ml/kg/day as "high" intensity. Categorical variables were compared using the chi-squared test, and continuous variables using-one way analysis of variance and the Kruskal--Wallis test. We assessed time-to-mortality censored at 1 year using Kaplan--Meier failure plots.

We used three methods to examine the association between UF^NET^ intensity and mortality. First, we fitted logistic regression and estimated risk-adjusted odds ratios (AORs) for high and moderate intensity, compared with low intensity UF^NET^ (reference), on 1-year mortality. Second, we fitted Gray's survival model \[[@CR22], [@CR23]\] to estimate risk-adjusted hazard ratios (AHRs) for time to mortality using four time nodes and five intervals (Additional file [1](#MOESM1){ref-type="media"}: S4). We adjusted for differences in age, sex, race, body mass index, history of liver disease and sequela from liver disease, admission for liver transplantation, admission for surgery, baseline glomerular filtration rate, Acute Physiologic and Chronic Health Evaluation (APACHE) III score, presence of sepsis, use of mechanical ventilation, percentage of FO before initiation of RRT, oliguria before initiation of RRT, time to initiation of RRT from ICU admission, MAP on first day of RRT initiation, cumulative vasopressor dose and cumulative fluid balance during RRT, first RRT modality and duration of RRT.

Third, in order to account for indication bias, we conducted a propensity score-matched analysis. Since the mortality associated with moderate (\> 20 to ≤ 25 ml/kg/day) vs high (\> 25 ml/kg/day) or moderate (\> 20 to ≤ 25 ml/kg/day) vs low (≤ 20 ml/kg/day) intensity UF^NET^ was not different (Table [1](#Tab1){ref-type="table"}), we combined the moderate and low-intensity groups into a single low-intensity group (reference). We then matched the low-intensity UF^NET^ (≤ 25 ml/kg/day) with the high-intensity UF^NET^ (\> 25 ml/kg/day) using propensity scores on a 1:1 basis without replacement, creating 258 matched pairs (Additional file [1](#MOESM1){ref-type="media"}: S5).Table 1Baseline characteristics of study population by net ultrafiltration Intensity≤ 20 ml/kg/day (*n* = 475)\> 20 to ≤ 25 ml/kg/day (*n* = 166)\> 25 ml/kg/day (*n* = 434)*p* valueAge (years), median (IQR)61 (52--69)59 (51--71)58 (48--70)0.16Male sex301 (63.4)114 (68.7)218 (50.2)\< 0.001Race Caucasian380 (80)136 (81.9)335 (77.2)0.018 African-American24 (5.1)6 (3.6)43 (9.9) Other71 (14.9)24 (14.5)56 (12.9)BMI (kg/m^2^), median (IQR)28.3 (24.2--34.3)27.7 (24.2--31.7)25.1 (21.9--29.3)\< 0.001Comorbid condition Hypertension169 (35.6)72 (43.4)161 (37.1)0.19 Diabetes121 (25.5)34 (20.5)97 (22.4)0.33 Cardiac disease84 (17.7)36 (21.7)99 (22.8)0.14 Heart failure70 (14.7)30 (18.1)86 (19.8)0.12 Vascular disease41 (8.6)16 (9.6)43 (9.9)0.79 Liver disease164 (34.5)47 (28.3)107 (24.7)0.005 Sequela from liver disease137 (28.8)43 (25.9)95 (21.9)0.056 Malignancy23 (4.8)4 (2.4)14 (3.2)0.26 Liver transplantation43 (9.1)13 (7.8)42 (9.7)0.77 Multiple comorbidity298 (62.7)93 (56)252 (58.1)0.19Surgical admission321 (67.6)122 (73.5)301 (69.4)0.72Medical admission131 (27.6)37 (22.3)112 (25.8)0.72Admission for liver transplantation102 (21.5)31 (18.7)53 (12.2)0.001Baseline serum creatinine (mg/dl), median (IQR)1.029 (0.81--1.27)1.035 (0.83--1.3)1.032 (0.8--1.3)0.89Baseline eGFR (ml/min/1.73 m^2^)  \> 90107 (22.5)27 (16.3)91 (20.9)0.54 60--90235 (49.5)97 (58.4)212 (48.9) 30--6089 (18.7)30 (18.1)92 (21.2) 15--3034 (7.2)8 (4.8)31 (7.1)  \< 1510 (2.1)4 (2.4)8 (1.8)APACHE III score, median (IQR)^a^95 (70--118)91 (71--116)91 (69--112)0.27Sepsis^a^128 (26.9)39 (23.5)138 (31.8)0.08Mechanical ventilation^a^353 (74.3)129 (77.7)329 (75.8)0.66Vasopressor^a^261 (54.9)87 (52.4)218 (50.2)0.36Oliguria before initiation of RRT^b^ Stage 250 (10.5)9 (5.4)21 (4.8)0.017 Stage 3406 (85.5)154 (92.8)402 (92.6)MAP during RRT (mmHg), mean (SD)^c^ All patients75.1 (0.58)77.5 (1.19)79.4 (0.62)\< 0.001 CRRT only (*n* = 386)72.7 (0.70)72.4 (1.89)77.5 (1.01)\< 0.001 IHD only (*n* = 210)85 (1.84)84.1 (2.85)82.1 (1.27)0.77 CRRT and IHD (*n* = 487)74.5 (0.91)79.1 (1.66)79.7 (0.98)0.002Vasopressor dose (NE), median (IQR)^c,d^ All patients0.11 (0.04--0.25)0.09 (0.03--0.21)0.09 (0.04--0.25)0.25 Patients on CRRT only0.14 (0.05--0.30)0.13 (0.03--0.25)0.10 (0.03--0.28)0.31 Patients on IHD only0.01 (0.01--0.03)0.06 (0.01--0.11)0.03 (0.01--0.07)0.67 Patients on both CRRT and IHD0.08 (0.03--0.16)0.08 (0.02--0.16)0.07 (0.03--0.19)0.85Data presented as *n* (%) unless stated otherwise*IQR* interquartile range, *BMI* body mass index, *eGFR* estimated glomerular filtration, *APACHE* Acute Physiology and Chronic Health Evaluation, *RRT* renal replacement therapy, *MAP* mean arterial pressure, *SD* standard deviation, *CRRT* continuous renal replacement therapy, *IHD* intermittent hemodialysis, *NE* norepinephrine equivalents^a^At intensive care unit admission^b^Patients were classified to have developed oliguria according to the maximum Kidney Disease Improving Global Outcome criteria based on urine output \[[@CR5]\]^c^On the day 1 of RRT^d^All vasopressors were standardized in terms of NE (Additional file [1](#MOESM1){ref-type="media"}: S3) \[[@CR30]--[@CR32]\]

We performed five sensitivity analyses and two subgroup analyses. First, we restricted the UF^NET^ intensity only up to 72 h from initiation of RRT. Second, we used an alternative definition of UF^NET^ intensity moving the threshold down as follows: low, \< 15 ml/kg/day; moderate, 15--20 ml/kg/day; and high, \> 20 ml/kg/day. Third, we moved the threshold up: low, \< 25 ml/kg/day; moderate, 25--30 ml/kg/day; and high, \> 30 ml/kg/day. Fourth, we divided the cohort into tertiles: low, ≤ 16.7 ml/kg/day; moderate, 16.7 to ≤ 27.7 ml/kg/day; and high, \> 27.7 ml/kg/day. Fifth, we performed quantitative bias analysis to assess the magnitude of a hypothetical unmeasured confounder that would be necessary to account for the association between UF^NET^ intensity and risk-adjusted mortality (Additional file [1](#MOESM1){ref-type="media"}: S6) \[[@CR24], [@CR25]\].

Sixth, we restricted our analyses only to the subgroup of patients with \> 20% FO. Seventh, we confined our analysis of UF^NET^ intensity to the hour (i.e., ml/kg/h) instead of the day among the subgroup of patients who only received CRRT as follows: low, \< 0.5 ml/kg/h; moderate, 0.5--1.0 ml/kg/h; and high, \> 1 ml/kg/h. Statistical analyses were performed using SAS 9.3 (SAS Institute, Cary, NC, USA), Gray's model used R 3.2.1, and quantitative bias analysis was performed using STATA 15 (STATCorp., TX, USA). All hypotheses tests were two-sided with a significance level of *p* \< 0.05.

Results {#Sec7}
=======

Study population and patient characteristics {#Sec8}
--------------------------------------------

Of 45,568 patients, we excluded patients with no available baseline weight (*n* = 2214), ICU duration ≤ 48 h (*n* = 18,032), death within 72 h of ICU admission (*n* = 663), chronic dialysis (*n* = 2386), admission for or with history of renal transplantation (*n* = 1232), serum creatinine ≥ 3.5 mg/dl within 1 year of hospitalization (*n* = 147) and missing data on fluid balance (*n* = 2810). Of 18,084 patients in whom cumulative fluid balance data were available, we excluded those with cumulative fluid balance \< 5% of body weight (*n* = 9900). Of patients with cumulative balance ≥ 5% of body weight (*n* = 8184), we excluded those who did not receive RRT (*n* = 7023) and patients without data on UF^NET^ (*n* = 86) (Additional file [1](#MOESM1){ref-type="media"}: Figure S1).

Of 1075 patients, the distribution of low, moderate and high-intensity UF^NET^ groups was 44.2%, 15.2% and 40.4%, respectively. Minor differences were noted among male sex, race and body mass index between the groups (Table [1](#Tab1){ref-type="table"}). There was a higher prevalence of liver disease (34.5%), sequela from liver disease (28.8%) and liver transplantation (21.5%) among those with low-intensity UF^NET^. There was a higher prevalence of oliguria in those who received moderate and high-intensity UF^NET^. Patients in the low-intensity UF^NET^ group had lower MAP compared with the moderate and high-intensity UF^NET^ groups (Table [1](#Tab1){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Table S1).

Cumulative FO before RRT initiation was lowest in the low-intensity group, compared with the moderate and high-intensity UF^NET^ groups (15.6% vs 17.3% vs 21% of body weight, respectively, *p* \< 0.001; Table [2](#Tab2){ref-type="table"}). Following initiation of RRT, the median cumulative FB for the low, medium and high-intensity UF^NET^ groups was 13.5 vs 22 vs 19 l, *p* \< 0.001; Table [2](#Tab2){ref-type="table"}). During RRT, the MAP was lower and the cumulative vasopressor dose was higher in the low-intensity UF^NET^ group compared with the moderate and high-intensity UF^NET^ groups (Table [2](#Tab2){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Table S1).Table 2Fluid balance, RRT characteristics and outcomes by intensity of net ultrafiltration≤ 20\
ml/kg/day\
(*n* = 475)\> 20 to ≤ 25\
ml/kg/day\
(*n* = 166)\> 25\
ml/kg/day\
(*n* = 434)*p* valueFluids administered in the first 24 h of ICU admission (L), median (IQR)5.3 (3.5--7.9)5.1 (3.6-- 7.8)5.23 (3.3--8.1)0.88Fluid balance after ICU admission (L), median (IQR) At 72 h7.9 (4.4--12)7.8 (4.7--13.3)7.6 (4.7--11.6)0.71 At 7 days10.1 (6.7--15.2)10.5 (6.4--15.7)10.1 (6.4--15.1)0.78 Average before RRT2.3 (1.2--4.4)2.7 (1.5--4.3)2.3 (1.2--4.2)0.33 Cumulative before RRT (%)15.6 (10--25)17.3 (9.9--28.6)21 (12.4--33.7)\< 0.001Duration from ICU admission to RRT (days), median (IQR)7 (2--13)5 (3--12)6 (3--16)0.27RRT duration (days), median (IQR)4.7 (1.5--11.7)8.7 (4.5--16.7)7 (3.1--12.7)\< 0.001Cumulative FB excluding UF^NET^ for duration of RRT (L), median (IQR)^a^13.5 (4.2--32.8)22 (8.9--45.1)19 (7.3--37.2)\< 0.001MAP for duration of RRT (mmHg), mean (SD)75.2 (0.6)77.4 (0.8)80.1 (0.53)\< 0.001Cumulative vasopressor dose for duration of RRT (NE), median (IQR)^a^15.7 (4.3--38.6)11.4 (1.2--34.7)8.1 (0.9--25.7)\< 0.001First RRT modality IHD121 (25.5)52 (31.3)127 (29.3)0.25 CRRT354 (74.5)114 (68.7)307 (70.7)CRRT duration (days), median (IQR)3.9 (1.5--7.7)5.8 (3.6--9.4)5.9 (2.8--9.5)\< 0.001UF^NET^ volume during CRRT (L), median (IQR)3.4 (0.9--10.2)11.6 (5.4--19.2)16.2 (7.5--28.4)\< 0.001IHD duration (days), median (IQR)2 (5--9)7 (3--13)4 (2--8)0.004UF^NET^ volume during IHD (L), median (IQR)5.5 (2.2--13.5)12.6 (4.4--19.7)9.2 (4--17.2)\< 0.001Both CRRT and IHD duration (days), median (IQR)14.7 (9.7--22.9)15.2 (9.2--21.9)10.7 (6.9--18.4)\< 0.001UF^NET^ volume during CRRT and IHD (L), median (IQR)19.5 (9.5--33.9)27.9 (18.5--42.1)26.6 (17.8--46.1)\< 0.001Hospital length of stay (days), median (IQR)32 (17--54)37.5 (23--65)37 (23--61)\< 0.001Hospital mortality272 (57.3)70 (42.2)187 (43.1)\< 0.0011-year mortality331 (69.7)100 (60.2)258 (59.4)0.003Renal recovery at 1 year^b^119 (25.1)48 (28.9)138 (31.8)0.078Renal recovery at 1 year in survivors^b^119 (82.6)48 (72.7)138 (78.4)0.25Data presented as *n* (%) unless stated otherwise*RRT* renal replacement therapy, *ICU* intensive care unit, *IQR* interquartile range, *FB* fluid balance, *UF*^*NET*^ net ultrafiltration, *MAP* mean arterial pressure, *SD* standard deviation, *NE* norepinephrine equivalents, *IHD* intermittent hemodialysis, *CRRT* continuous renal replacement therapy^a^All vasopressors were standardized in terms of NE (Additional file [1](#MOESM1){ref-type="media"}: S3) \[[@CR30]--[@CR32]\]^b^Renal recovery was defined as alive and independent of RRT at 1 year

The median duration of RRT for the low, moderate and high-intensity UF^NET^ groups was 4.7 vs 8.7 vs 7 days, respectively (*p* \< 0.001). The median duration of CRRT was 3.9 vs 5.8 vs 5.9 days (*p* \< 0.001) and the median UF^NET^ volume was 3.4 vs 11.6 vs 16.2 L (*p* \< 0.001). The median duration of IHD was 2 vs 7 vs 4 days (*p* = 0.004) and the median UF^NET^ volume was 5.5 vs 12.6 vs 9.2 L (*p* \< 0.001). The median duration of RRT for patients who received both CRRT and IHD was 14.7 vs 15.2 vs 10.7 days (*p* \< 0.001) and the median UF^NET^ volume was 19.5 vs 27.9 vs 26.6 L (*p* \< 0.001). The median hospital length of stay was 32 vs 37.5 vs 37 days (*p* \< 0.001) (Table [2](#Tab2){ref-type="table"}). This shorter length of stay among patients with low-intensity UF^NET^ was primarily due to higher mortality in this group. However, there was no difference in renal recovery at 1 year (25.1% vs 28.9% vs 31.8%, *p* = 0.078) as well as within the subgroup of survivors at 1 year (82.6% vs 72.7% vs 78.4%, *p* = 0.25) between the three groups.

Association between UF^NET^ intensity and mortality {#Sec9}
---------------------------------------------------

The crude hospital and 1-year mortality was higher among the low-intensity group compared with the moderate and high-intensity UF^NET^ groups: 69.7% vs 60.2% vs 59.4% (*p* = 0.003), respectively (Table [2](#Tab2){ref-type="table"}, Fig. [1a](#Fig1){ref-type="fig"}). Using logistic regression, high-intensity compared with low-intensity UF^NET^ was associated with lower 1-year mortality (AOR 0.61, 95% CI 0.41--0.93, *p* = 0.02, *C*-statistic 0.811; Table [3](#Tab3){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Table S2). This association persisted using UF^NET^ as a continuous variable (AOR 0.98, 95% CI 0.97--0.99, *p* = 0.005; Additional file [1](#MOESM1){ref-type="media"}: Table S3). Compared with UF^NET^ of 0--5 ml/kg/day, increasing UF^NET^ intensity was associated with a trend toward lower odds of death (*C*-statistic -- 0.813; Fig. [1b](#Fig1){ref-type="fig"}), whereas moderate-intensity compared with low-intensity UF^NET^ was not associated with mortality (AOR 0.81, 95% CI 0.48--1.35, *p* = 0.41; Additional file [1](#MOESM1){ref-type="media"}: Table S2).Fig. 1**a**. Association between net ultrafiltration intensity and time to mortality. Kaplan--Meier failure plots by UF^NET^ intensity for probability of death over 1 year from ICU admission in overall cohort (*n* = 1075). Red line, low-intensity UF^NET^ (≤ 20 ml/kg/day); blue line, moderate-intensity UF^NET^ (\> 20 to ≤ 25 ml/kg/day); green line, high-intensity UF^NET^ (\> 25 ml/kg/day). Probability of death highest in low-intensity compared with moderate and high-intensity UF^NET^ groups (log-rank *p* \< 0.001). **b**. Association between net ultrafiltration intensity and risk-adjusted 1-year mortality. Shown are adjusted odds ratio with 95% CI for association between UF^NET^ intensity and mortality. Increasing UF^NET^ intensity associated with trend toward lower mortality. Odds ratios adjusted for differences in age, sex, race, BMI, history of liver disease and sequela from liver disease, admission for liver transplantation, admission for surgery, baseline glomerular filtration rate, Acute Physiology and Chronic Health Evaluation III score, presence of sepsis, use of mechanical ventilation, percentage of cumulative fluid overload before initiation of RRT, oliguria before initiation of RRT, time to initiation of RRT from ICU admission, MAP on first day of RRT initiation, cumulative vasopressor dose and cumulative fluid balance during RRT, first RRT modality and duration of RRT. ICU intensive care unitTable 3Association between UF^NET^ intensity and 1-year risk-adjusted mortalityCovariatesUnadjusted odds ratio (95% CI)*p* valueAdjusted^a^ odds ratio (95% CI)*p* valueModerate vs low-intensity UF^NET^ (reference)0.65 (0.42--0.94)0.0240.81 (0.48--1.35)0.41High vs low-intensity UF^NET^ (reference)0.64 (0.49--0.85)0.0020.61 (0.41--0.93)0.02*UF*^*NET*^ net ultrafiltration, *CI* confidence interval, FO fluid overload, *RRT* renal replacement therapy, *ICU* intensive care unit^a^Adjusted for age, sex, race, body mass index, history of liver disease and sequela from liver disease, admission for liver transplantation, admission for surgery, baseline glomerular filtration rate, Acute Physiology and Chronic Health Evaluation III score, presence of sepsis, use of mechanical ventilation, percentage of FO before initiation of RRT, oliguria before initiation of RRT, time to initiation of RRT from ICU admission, mean arterial pressure on first day of RRT initiation, cumulative vasopressor dose and cumulative fluid balance during RRT, first RRT modality and duration of RRT

Using Gray's model, high-intensity compared with low-intensity UF^NET^ had variable association with mortality. Early on after ICU admission, high-intensity UF^NET^ was associated with lowest risk of death that was subsequently attenuated over time, but nevertheless persisted up to 39 days after ICU admission (AHR range 0.50--0.73, *p* \< 0.001; Table [4](#Tab4){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Figure S3A). Subsequently, between 39 and 365 days, high-intensity UF^NET^ was not associated with mortality (AHR range 0.76--1.02). High-intensity compared with moderate-intensity UF^NET^ was only associated with lower risk of death up to 15 days (AHR 0.53, 95% CI 0.33--0.86; Additional file [1](#MOESM1){ref-type="media"}: Table S5 and Figure S3C).Table 4Association between intensity of net ultrafiltration and time to mortality from Gray's modelCharacteristicAdjusted hazard ratio (95% CI) by time interval^a^*p* value5--15 days15--23 days23--39 days39--91 days91--365 daysHigh vs low UF^NET^0.50 (0.35--0.71)0.62 (0.46--0.82)0.73 (0.55--0.97)0.76 (0.56--1.04)1.02 (0.71--1.47)\< 0.001High vs moderate UF^NET^0.53 (0.33--0.86)0.69 (0.46--1.02)0.75 (0.52--1.09)0.77 (0.518--1.142)1.16 (0.72--1.85)0.039Moderate vs low UF^NET^0.98 (0.62--1.57)0.87 (0.59--1.27)0.996 (0.69--1.43)1.01 (0.69--1.47)0.844 (0.53--1.34)0.91Shown are adjusted hazard ratios estimated from Gray's model for association between intensity of UF^NET^ and mortality for each time interval. Models included five time intervals and four time nodes with the default timing of nodes chosen by the statistical program based on the number of observations within each time interval. Hazard ratio \< 1 suggests that UF^NET^ intensity is associated with lower mortality, and hazard ratio \> 1 suggests UF^NET^ intensity is associated with higher mortality. *p* values reported are for the ranges of hazard ratios from the model*CI* confidence interval, *UF*^*NET*^ net ultrafiltration, FO fluid overload, *RRT* renal replacement therapy, *ICU* intensive care unit^a^Adjusted for age, sex, race, body mass index, history of liver disease and sequela from liver disease, admission for liver transplantation, admission for surgery, baseline glomerular filtration rate, Acute Physiology and Chronic Health Evaluation III score, presence of sepsis, use of mechanical ventilation, percentage of FO before initiation of RRT, oliguria before initiation of RRT, time to initiation of RRT from ICU admission, mean arterial pressure on first day of RRT initiation, cumulative vasopressor dose and cumulative fluid balance during RRT, first RRT modality and duration of RRT

After propensity matching, 258 matched pairs were created wherein patients with UF^NET^ intensity ≤ 25 ml/kg/day had similar baseline characteristics compared with UF^NET^ intensity \> 25 ml/kg/day, except for cumulative vasopressor dose (Additional file [1](#MOESM1){ref-type="media"}: Table S4). Patients with UF^NET^ intensity \> 25 ml/kg/day compared with ≤ 25 ml/kg/day had lower 1-year mortality (57% vs 67.8%, *p* = 0.01; Fig. [2](#Fig2){ref-type="fig"}), which persisted after adjusting for vasopressor dose (AOR 0.63, 95% CI 0.44--0.90, *p* = 0.011).Fig. 2Association between net ultrafiltration intensity and time to mortality in propensity-matched cohort. Kaplan--Meier failure plots by UF^NET^ for probability of death over 1 year from ICU admission among patients with UF^NET^ ≤ 25 ml/kg/day (*n* = 258) compared with propensity-matched patients with UF^NET^ \> 25 ml/kg/day (*n* = 258). Red line, UF^NET^ ≤ 25 ml/kg/day; green line, UF^NET^ \> 25 ml/kg/day. Probability of death lower among patients who received UF^NET^ \> 25 ml/kg/day compared with UF^NET^ ≤ 25 ml/kg/day (log-rank *p* \< 0.001). ICU intensive care unit

Sensitivity analyses {#Sec10}
--------------------

When UF^NET^ intensity calculation was limited within 72 h of initiation of RRT, high-intensity UF^NET^ was associated with lower mortality (AOR 0.56, 95% CI 0.35--0.88, *p* = 0.013; Table [5](#Tab5){ref-type="table"}). Using the alternative thresholds of low, moderate and high-intensity UF^NET^ of \< 15 ml/kg/h, 15--20 ml/kg/h and \> 20 ml/kg/h, respectively, we found UF^NET^ intensity \> 20 ml/kg/h was associated with lower mortality (AOR 0.63, 95% CI 0.41--0.97, *p* = 0.038). Similar results were found moving the threshold up (AOR 0.58, 95% CI 0.34--0.99, *p* = 0.04; Table [5](#Tab5){ref-type="table"}) and using tertile cutoff values (AOR 0.61, 95% CI 0.39--0.97, *p* = 0.037; Table [5](#Tab5){ref-type="table"}). The quantitative bias analysis indicated that our results would be robust unless an unmeasured confounder was at least twice as prevalent among patients who received high-intensity UF^NET^ as among those with low-intensity UF^NET^ (Additional file [1](#MOESM1){ref-type="media"}: Figure S4). The unmeasured confounder should have an OR \< 0.7 (i.e., reduced risk of death by more than 30%) to mask a null association between high-intensity UF^NET^ and risk-adjusted mortality (Additional file [1](#MOESM1){ref-type="media"}: S6 and Figure S4).Table 5Sensitivity and subgroup analyses of net ultrafiltration intensity and mortalityCharacteristicNet ultrafiltration intensityAdjusted odds ratio (95% CI)^a^*p* valueSensitivity analysis UF^NET^ up to 72 h after RRT initiation^b^High vs low0.56 (0.35--0.88)0.013Moderate vs low1.10 (0.58--2.11)0.76 Alternative UF^NET^ threshold^c^High vs low0.63 (0.41--0.97)0.038Moderate vs low0.91 (0.53--1.58)0.74 Alternative UF^NET^ threshold^d^High vs low0.58 (0.34--0.99)0.044Moderate vs low0.66 (0.43--1.01)0.053 Alternative UF^NET^ threshold^e^High vs low0.61 (0.39--0.97)0.0371Moderate vs low0.69 (0.45--1.07)0.096Subgroup analysis UF^NET^ among subgroup of patients with cumulative FB \> 20% before RRT^f^High vs low0.52 (0.26--1.05)0.07Moderate vs low0.74 (0.29--1.84)0.51 Alternative UF^NET^ threshold among subgroup of patients who only received CRRT^g^High vs low0.41 (0.24--0.71)0.0013Moderate vs low0.68 (0.39--1.18)0.17*CI* confidence interval, *UF*^*NET*^ net ultrafiltration, *RRT* renal replacement therapy, *FB* fluid balance, *CRRT* continuous renal replacement therapy, FO fluid overload, *ICU* intensive care unit^a^Adjusted for differences in age, sex, race, body mass index, history of liver disease and sequela from liver disease, admission for liver transplantation, admission for surgery, baseline glomerular filtration rate, Acute Physiology and Chronic Health Evaluation III score, presence of sepsis, use of mechanical ventilation, percentage of FO before initiation of RRT, oliguria before initiation of RRT, time to initiation of RRT from ICU admission, mean arterial pressure on first day of RRT initiation, cumulative vasopressor dose and fluid balance during RRT, first RRT modality and duration of RRT^b^UF^NET^ intensity calculated using RRT duration of 72 h as a cutoff value in 1075 patients^c^Threshold for low, moderate and high UF^NET^ varied as follows in 1075 patients: low, \< 15 ml/kg/day; moderate, 15--20 ml/kg/day; and high, \> 20 ml/kg/day^d^Threshold for low, moderate and high UF^NET^ varied as follows in 1075 patients: low, \< 25 ml/kg/day; moderate, 25--30 ml/kg/day; and high, \> 30 ml/kg/day^e^Threshold for low, moderate and high UF^NET^ based on stratifying the cohort of 1075 patients into tertiles: low, ≤ 16.7 ml/kg/day; moderate, 16.7 to ≤ 27.7 ml/kg/day; and high, \> 27.7 ml/kg/day^f^UF^NET^ calculated within subgroup of 465 patients with cumulative FB \> 20% before RRT initiation^g^Threshold for low, moderate and high UF^NET^ varied among subgroup of 487 patients who only received CRRT as follows: low, \< 0.5 ml/kg/h; moderate, 0.5--1.0 ml/kg/h; and high, \> 1 ml/kg/h

Subgroup analyses {#Sec11}
-----------------

High-intensity UF^NET^ was associated with a trend toward lower mortality among patients with \> 20% FO (AOR 0.52, 95% CI 0.26--1.05, *p* = 0.07; Table [5](#Tab5){ref-type="table"}). For patients receiving CRRT, UF^NET^ intensity \> 1.0 ml/kg/h compared with UF^NET^ intensity \< 0.5 ml/kg/h was associated with lower odds of death (AOR 0.41, 95% CI 0.24--0.71, *p* = 0.0013).

Discussion {#Sec12}
==========

We found that UF^NET^ intensity \> 25 ml/kg/day, compared with \< 20 ml/kg/day, was independently associated with lower risk-adjusted 1-year mortality in critically ill patients with FO. Using Gray's model, this survival benefit was greater early on after ICU admission and persisted up to 39 days. In the propensity-matched analysis, UF^NET^ \> 25 ml/kg/day, compared with ≤ 25 ml/kg/day, was also associated with lower risk of death. To our knowledge, this is the first study in the literature examining the association between UF^NET^ intensity and long-term mortality.

Our finding is somewhat analogous to the association between intensity of solute control and mortality in critically ill patients receiving RRT in which a threshold intensity of at least 20--25 ml/kg/h of effluent dosing in CRRT or KT/V of 1.2--1.4 per session in patients receiving IHD is associated with improved survival \[[@CR26], [@CR27]\]. However, in contrast to studies on solute control, the optimal "dosing" for UF^NET^ in critically ill patients with fluid overload is unclear. In our study, we first explored whether there was an association between UF^NET^ dose and mortality, and then aimed to determine the overall "average dose" that is associated with a long-term mortality benefit. It is important to note that our finding does not suggest that UF^NET^ should be dosed \> 25 ml/kg/day throughout the duration of fluid removal. Day-to-day dosing may vary in patients depending on the severity of fluid overload, patient tolerability and hemodynamics.

In our study only 40% of patients received intensive UF^NET^, whereas 44% of patients received less intensive UF^NET^ that has implications for care. Unlike a prescription for solute clearance, the concept of a minimum or adequate "dose" for volume clearance is not usually considered in clinical practice. Although patients who received less intensive UF^NET^ were hemodynamically unstable in our study, our findings persisted after accounting for hemodynamics, vasopressor dose and severity of illness, suggesting that less intensive UF^NET^ per se might be associated with mortality. These findings may suggest that failure to tolerate UF^NET^ \> 25 ml/kg/day may portend a poor prognosis and, conversely, tolerating UF^NET^ \> 25 ml/kg/day may be a predictor of recovery and lower mortality in critically ill patients with fluid overload.

Our study addresses an important knowledge gap not addressed by prior studies. While numerous studies have documented an association between the severity of FO and incremental risk of death \[[@CR3], [@CR4]\], none examined the UF^NET^ intensity--mortality relationship. Using the Program to Improve Care in Acute Renal Disease (PICARD) study, Bouchard et al. \[[@CR4]\] found that patients in whom FO was corrected during RRT had lower mortality than those who remained fluid overloaded despite RRT. Using the Randomized Evaluation of Normal versus Augmented Level of Renal Replacement Therapy (RENAL RRT) cohort, Bellomo et al. \[[@CR2]\] found that a negative fluid balance during RRT was associated with a mortality benefit. However, we asked a different question: does UF^NET^ intensity and a threshold "dose" of UF^NET^ matter in the treatment of FO independent of fluid balance?

There may be several biologic explanations for the association between UF^NET^ intensity and outcome. First, intensive UF^NET^ may reduce prolonged exposure to FO and modify host response, and could reduce the incidence of subsequent organ dysfunction \[[@CR28]\]. Second, the salutary effects of intensive UF^NET^ may be mediated through unknown marker clearance independent of fluid balance since the association persisted despite controlling for cumulative fluid balance. Third, clinicians who decide to initiate intensive UF^NET^ may select for a unique group of patients to monitor and carefully titrate fluid removal. Fourth, clinicians and nurses may also have a broad variation in how they prescribe and/or practice UF^NET^ in the real world, which may be associated with differences in outcomes \[[@CR29]\].

The strengths of our study was that it was robust to three different methods of sensitivity analysis. We accounted for confounding due to severity of illness, hemodynamics, vasopressor dose and cumulative fluid balance before and during RRT. Using Gray's model, we found that high-intensity UF^NET^ was associated with survival only up to 39 days after ICU admission. This finding is in contrast with the logistic model and propensity-matched analyses, which showed mortality benefit up to 1 year. This discordant finding is due to the differences in the models that were used. In Gray's model, the number of events between high-intensity and low-intensity UF^NET^ groups was not different within the time interval of 39--365 days. Using the logistic regression model, however, a lower odds of cumulative deaths occurred by 1 year in the high-intensity UF^NET^ group compared with the low-intensity UF^NET^ group.

Our study is not without limitations. First, given the observational nature, it is not possible to make causal inferences between UF^NET^ intensity and outcomes. Second, we do not know precisely whether a UF^NET^ threshold \> 25 ml/kg/day is associated with better outcomes, although our findings were robust to several sensitivity analyses. Third, our single-center study may not be generalizable to other ICU populations. Nevertheless, our study included patients typical of an academic medical center ICU population. Fourth, we were unable to distinguish whether patients received low-intensity UF^NET^ due to low prescription, failure to remove fluid (e.g., circuit downtime, trip to operating room, etc.) or other variations in practice with respect to fluid removal. Fifth, although the sensitivity analysis indicated that any unmeasured confounder would need to be highly prevalent and have an OR \< 0.7 to mask a null association, it is possible that there may be more than one residual confounder and that it may not be a binary variable.

Conclusion {#Sec13}
==========

In summary, among critically ill patients with ≥ 5% FO receiving RRT, our study found that UF^NET^ intensity \> 25 ml/kg/day is associated with lower risk-adjusted 1-year mortality compared with \< 20 ml/kg/day. Whether this association between UF^NET^ intensity \> 25 ml/kg/day and lower mortality risk is just a marker for recovery or a mediator needs to be refuted or confirmed in future prospective randomized controlled trials.
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:   Adjusted hazard ratio

AKI

:   Acute kidney injury

AOR

:   Adjusted odds ratio

APACHE

:   Acute Physiology and Chronic Health Evaluation

CRRT

:   Continuous renal replacement therapy

CVVH

:   Continuous venovenous hemofiltration

CVVHD

:   Continuous venovenous hemodialysis

CVVHDF

:   Continuous venovenous hemodiafiltration

FO

:   Fluid overload

IHD

:   Intermittent hemodialysis
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:   Mean arterial pressure
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:   Renal replacement therapy

SCUF

:   Slow continuous ultrafiltration

UF^NET^

:   Net ultrafiltration
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